Clinical Trials Logo

Clinical Trial Summary

Multicentre Study of nomacopan in Paediatric Haematopoietic Stem-Cell Transplant Associated Thrombotic Microangiopathy


Clinical Trial Description

This is an open-label, multi-centre study of two-parts, Part A and B, includes 24 weeks of treatment, safety follow up after 30 days. Part A: dose algorithm, safety and efficacy Part B: safety and efficacy ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04784455
Study type Interventional
Source AKARI Therapeutics
Contact Wynne W Davies, MD
Phone 02080040268
Email medical.monitors@akaritx.com
Status Recruiting
Phase Phase 3
Start date February 1, 2021
Completion date December 2025

See also
  Status Clinical Trial Phase
Recruiting NCT04098445 - TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients
Recruiting NCT03605511 - TTP and aHUS in Complicated Pregnancies
Not yet recruiting NCT05996679 - Automated Surveillance, Alert, and Rapid Diagnosis of Thrombotic Microangiopathies: the ASARD-TMA Study
Completed NCT02222545 - Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies Phase 2
Recruiting NCT06102694 - Identification of Plasma Biomarkers for Early Diagnosis of Transplant-associated Thrombotic Microangiopathy
Completed NCT03252925 - A Safety and Efficacy Study of NAC in Patients With TA-TMA Phase 3
Recruiting NCT05855083 - Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA Phase 2
Completed NCT03384693 - Defibrotide TMA Prophylaxis Pilot Trial Phase 2
Not yet recruiting NCT05702996 - Multicenter, Uncontrolled Pilot Study Evaluating the Efficacy of Eculizumab in the Treatment of Gemcitabine-induced Thrombotic Microangiopathies Phase 3
Not yet recruiting NCT02373267 - Screening of TMA Patients für ADAMTS13 Activity (Adamscreen) N/A
Recruiting NCT06098378 - Study of Patients With Thrombotic Microangiopathy Associated With Mitomycin C, Treated or Not With Eculizumab
Completed NCT02134171 - Early Predictive Factors of Cardiac and Cerebral Involvement in TMA N/A
Not yet recruiting NCT06182410 - Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma Phase 2
Withdrawn NCT04970004 - Study in Adult and Pediatric Patients With HSCT-TMA
Recruiting NCT03205995 - Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome Phase 3
Active, not recruiting NCT04570397 - Ravulizumab and COVID-19 Phase 3
Recruiting NCT05634928 - Construction of a Database for TMA
Completed NCT03518203 - Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients Phase 2
Recruiting NCT04745195 - Complement Prospective Evaluation of Thrombotic Microangiopathy on Endothelium
Recruiting NCT06291415 - The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP) Phase 1